Biotech Values

[RockRat]

You're likely referring to the early November FDA hearings about biosimilar/FoB regulations, with input from pharma execs.

A draft document is apparently out, but the FDA won't comment on it:

http://thehill.com/blogs/healthwatch/prescription-drug-policy/119735-fda-calls-for-hearing-on-biosimilars-legislation

I haven't read the whole thing yet, but it looks as though anyone can submit an electronic comment.

Regards, RockRat